Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Bertilsson

Showing results (201-210 of 263) with videos related to

Pageof 27
Sort By:
Clinical Pharmacology and Therapeutics|August 1, 1996
Disposition of fluvoxamine in humans is determined by the polymorphic CYP2D6 and also by the CYP1A2 activityJ A Carrillo, M L Dahl, J O Svensson, et al.
Acta Psychiatrica Scandinavica|March 1, 1984
CSF monoamine metabolites in melancholiaM Asberg, L Bertilsson, B Mårtensson, et al.
Analytical Chemistry|July 1, 1972
Quantitative determination of 5-hydroxyindole-3-acetic acid in cerebrospinal fluid by gas chromatography-mass spectrometryL Bertilsson, A J Atkinson, J R Althaus, et al.
Clinical Pharmacology and Therapeutics|December 1, 1999
The roles of cytochrome P450 3A4 and 1A2 in the 3-hydroxylation of quinine in vivoR A Mirghani, U Hellgren, P A Westerberg, et al.
Regulatory Peptides|February 24, 1994
Quantitation of N-terminally extended tachykinins in cerebrospinal fluid from healthy subjectsG Toresson, E Brodin, C de las Carreras, et al.
Pharmacogenetics|February 1, 1992
Polymorphic hydroxylation of S-mephenytoin and omeprazole metabolism in Caucasian and Chinese subjectsT Andersson, C G Regårdh, Y C Lou, et al.
Clinical Pharmacology and Therapeutics|August 10, 2007
Effect of terbinafine and voriconazole on the pharmacokinetics of the antidepressant venlafaxineV-V Hynninen, K T Olkkola, L Bertilsson, et al.
Lakartidningen|May 6, 1992
[Genotyping for drug metabolism capacity can give valuable clinical information]M Ingelman-Sundberg, I Johansson, M L Dahl, et al.
Clinical Pharmacology and Therapeutics|October 24, 2001
Inhibition of cytochrome P4502D6 activity with paroxetine normalizes the ultrarapid metabolizer phenotype as measured by nortriptyline pharmacokinetics and the debrisoquin testK Laine, G Tybring, S Härtter, et al.
Clinical Pharmacology and Therapeutics|September 1, 1984
Nortriptyline and debrisoquine hydroxylations in Ghanaian and Swedish subjectsN M Woolhouse, K K Adjepon-Yamoah, B Mellström, et al.
Pageof 27

Showing results (201-210 of 263) with videos related to

Sort By:
Pageof 27
Clinical Pharmacology and Therapeutics|August 1, 1996
Disposition of fluvoxamine in humans is determined by the polymorphic CYP2D6 and also by the CYP1A2 activityJ A Carrillo, M L Dahl, J O Svensson, et al.
Acta Psychiatrica Scandinavica|March 1, 1984
CSF monoamine metabolites in melancholiaM Asberg, L Bertilsson, B Mårtensson, et al.
Analytical Chemistry|July 1, 1972
Quantitative determination of 5-hydroxyindole-3-acetic acid in cerebrospinal fluid by gas chromatography-mass spectrometryL Bertilsson, A J Atkinson, J R Althaus, et al.
Clinical Pharmacology and Therapeutics|December 1, 1999
The roles of cytochrome P450 3A4 and 1A2 in the 3-hydroxylation of quinine in vivoR A Mirghani, U Hellgren, P A Westerberg, et al.
Regulatory Peptides|February 24, 1994
Quantitation of N-terminally extended tachykinins in cerebrospinal fluid from healthy subjectsG Toresson, E Brodin, C de las Carreras, et al.
Pharmacogenetics|February 1, 1992
Polymorphic hydroxylation of S-mephenytoin and omeprazole metabolism in Caucasian and Chinese subjectsT Andersson, C G Regårdh, Y C Lou, et al.
Clinical Pharmacology and Therapeutics|August 10, 2007
Effect of terbinafine and voriconazole on the pharmacokinetics of the antidepressant venlafaxineV-V Hynninen, K T Olkkola, L Bertilsson, et al.
Lakartidningen|May 6, 1992
[Genotyping for drug metabolism capacity can give valuable clinical information]M Ingelman-Sundberg, I Johansson, M L Dahl, et al.
Clinical Pharmacology and Therapeutics|October 24, 2001
Inhibition of cytochrome P4502D6 activity with paroxetine normalizes the ultrarapid metabolizer phenotype as measured by nortriptyline pharmacokinetics and the debrisoquin testK Laine, G Tybring, S Härtter, et al.
Clinical Pharmacology and Therapeutics|September 1, 1984
Nortriptyline and debrisoquine hydroxylations in Ghanaian and Swedish subjectsN M Woolhouse, K K Adjepon-Yamoah, B Mellström, et al.
Pageof 27